Individuals affected by PWS, AS, or Dup15q may benefit from newborn screening followed by early targeted interventions that may become available in the next 5 years.8,9,10 For PWS, diagnosis in infancy allows for early initiation of growth hormone treatment to improve long-term outcomes.11 For AS and Dup15q, most infants do not receive a diagnosis that would allow intervention in the first year of life. The gene discussed is GH1; the disease is Prader-Willi syndrome.